How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Virology Specimen Collection Market
- By Specimen Type: Nasopharyngeal Swabs, Oropharyngeal Swabs, Saliva Samples, Blood Samples, Sputum Samples, Stool Samples
- By Product Type: Swabs, Transport Media, Collection Kits, Blood Collection Tubes, Saliva Collection Devices
- By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Clinics, Point-of-Care Testing Centers
- By Virus Type: Influenza Virus, SARS-CoV-2, Human Immunodeficiency Virus (HIV), Hepatitis Viruses, Herpes Simplex Virus, Respiratory Syncytial Virus (RSV)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Nasopharyngeal Swabs leads By Specimen Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.172 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.180 →
Full report · locked preview
Everything inside the Virology Specimen Collection Market report
A complete, evidence-based study - 11 chapters and 121 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Specimen Type 6
Product Type 5
End User 5
Virus Type 6
Companies profiled
Thermo Fisher Scientific
Copan Diagnostics
Puritan Medical Products
Hologic Inc.
BD (Becton
Dickinson and Company)
Roche Diagnostics
Quidel Corporation
Greiner Bio-One International GmbH
Noble Biosciences
Zymo Research Corporation
Mawi DNA Technologies
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Copan Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Puritan Medical Products
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Quidel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Greiner Bio-One International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Noble Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Zymo Research Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mawi DNA Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sarstedt AG & Co.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Fisher Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Norgen Biotek Corp.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →BioIVT
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,653M by 2033 · 5.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Nasopharyngeal Swabs43.0
- Oropharyngeal Swabs12.3
- Saliva Samples12.0
- Blood Samples10.0
- Sputum Samples9.7
- Stool Samples13.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$582.6M → $795.7M · 4.0%
Europe$406.0M → $626.6M · 5.6%
Asia Pacific$370.7M → $551.5M · 5.1%
Latin America$229.5M → $329.4M · 4.6%
Middle East and Africa$176.5M → $296.4M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.182026
5.192027
5.202028
5.222029
5.212030
5.222031
5.252032
5.262033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific20.7
- Copan Diagnostics20.3
- Puritan Medical Products8.1
- Hologic Inc.9.0
- BD (Becton7.8
- Dickinson and Company)6.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Specimen Type25.8%
Product Type22.2%
End User21.3%
Virus Type30.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.6
- Europe24.1
- Asia Pacific21.2
- Latin America12.7
- Middle East and Africa11.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 85 | 73 | 94 | 83 | 88 | 74 | 83 |
| Copan Diagnostics | 78 | 75 | 82 | 74 | 86 | 70 | 78 |
| Puritan Medical Products | 71 | 78 | 66 | 84 | 65 | 87 | 75 |
| Hologic Inc. | 66 | 69 | 71 | 63 | 75 | 72 | 69 |
| BD (Becton | 65 | 57 | 54 | 74 | 71 | 60 | 64 |
| Dickinson and Company) | 66 | 55 | 48 | 67 | 49 | 64 | 58 |
| Roche Diagnostics | 54 | 51 | 61 | 64 | 62 | 41 | 56 |
| Quidel Corporation | 46 | 54 | 37 | 60 | 48 | 55 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Copan Diagnostics
- Puritan Medical Products
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Copan Diagnostics | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Puritan Medical Products | ◐ | ◐ | − | ◐ | ✓ | ✓ |
| Hologic Inc. | − | ◐ | ◐ | − | ◐ | ✓ |
| BD (Becton | − | ◐ | − | ✓ | ◐ | ◐ |
| Dickinson and Company) | ◐ | − | − | − | ◐ | − |
| Roche Diagnostics | − | ◐ | ◐ | − | ◐ | − |
| Quidel Corporation | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific83
2Copan Diagnostics78
3Puritan Medical Products75
4Hologic Inc.69
5BD (Becton64
6Dickinson and Company)58
7Roche Diagnostics56
8Quidel Corporation50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificCopan Diagnostics
Challenger2
Strong scale, closing on the leaders.
Puritan Medical ProductsHologic Inc.
Contender2
Focused players with pockets of strength.
BD (BectonDickinson and Company)
Niche2
Specialists in a single segment or region.
Roche DiagnosticsQuidel Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Specimen Type in North America, then scale across Virology Specimen Collection Market — a $660M beachhead inside a $10.7B market.
Beachhead (SOM)$660Mobtainable near-term
Serviceable (SAM)$3.81Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Nasopharyngeal Swabs
Best fit — highest urgency & budget in Specimen Type.
Economic buyer78 fit
Oropharyngeal Swabs
Strong fit — clear ROI and a fast path to value.
End user70 fit
Saliva Samples
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Specimen Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Specimen Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Virology Specimen Collection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation14%
Closed-won7%
$9.2KCAC
$52KLTV
5.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Virology Specimen Collection Market is a durable-growth opportunity — $6.21B by 2033, compounding at 7.9%.
TAM · 2025$3.39Btoday
TAM · 2033$6.21Bforecast
CAGR7.9%2027–2033
Cumulative$42.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.21BTotal addressable market
SAM$2.55BServiceable available market
SOM$539MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Specimen Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Specimen Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.21BLarge & growingTAM by 2033 at 7.9% CAGR
$2.55BServiceable nowreachable with today’s model
$539MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.85BBear5.1% CAGR
$6.21BBase7.9% CAGR
$7.95BBull10.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Virology Specimen Collection Market — a $2.46B market by 2033. Plan: grow share from 9.1% to 16.3%.
Market size · 2033$2.46Btotal addressable
Market CAGR11.7%2027–2033
Target share16.3%from 9.1% today
Revenue ambition$401Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 16.3% | Behind |
| Revenue | $208M | $401M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.2% | 42.7% | Behind |
| Customer retention | 87.4% | 92.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Specimen Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Specimen Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $45M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Specimen Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Virology Specimen Collection Market conversation — a $6.66B market you can size, segment and defend in minutes.
Market size · 2033$6.66Btotal opportunity
Growth4.3%CAGR to 2033
Addressable buyers1,249+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Specimen Type
Goal Grow share in Specimen Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 4 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificCopan DiagnosticsPuritan Medical ProductsHologic Inc.BD (BectonDickinson and Company)Roche DiagnosticsQuidel Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Virology Specimen Collection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Virology Specimen Collection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Virology Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportVirgin Paper Pipet Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportVirginiamycin Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportViral Warts Treatment Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportViral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportViral Vectors Gene Therapy Market
Market size, share, segmentation and regional forecast.
$948M market · 2025 base year
View reportViral Vector Purification Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportViral Vector Production (Research-use) Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportViral Vector Packaging Services Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportViral Vector Manufacturing Services Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportViral Vector Manufacturing Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportViral Vector CDMO Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.